Difference in Neutropenia due to Administration Schedule of TAS-102.

Yoshida, Yoichiro; Aisu, Naoya; Mogi, Ai; Komono, Akira; Sakamoto, Ryohei; Kojima, Daibo; Mera, Toshiyuki; Hasegawa, Suguru.

Afiliação

Yoshida Y; aDepartment of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
Aisu N; aDepartment of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
Mogi A; bDivision of Oncology, Hematology and Infectious Diseases, Department of Internal Medicine, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
Komono A; aDepartment of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
Sakamoto R; aDepartment of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
Kojima D; aDepartment of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
Mera T; aDepartment of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan.
Hasegawa S; aDepartment of Gastroenterological Surgery, Fukuoka University Faculty of Medicine, Fukuoka, Japan.

Case Rep Oncol ; 10(1): 226-229, 2017.

Article em En | MEDLINE | ID: mdl-28611635

ABSTRACT

TAS-102 significantly improves overall survival in patients with metastatic colorectal cancer. The most common adverse event of TAS-102 is bone marrow suppression, which leads to neutropenia. The incidence of neutropenia is high, and there is no known effective prevention method. Furthermore, the administration method of TAS-102 is complicated. We reported that neutropenia could be avoided by changing to a simple administration method of TAS-102.

Palavras-chave

Chemotherapy; Colorectal cancer; Neutropenia; TAS-102

Texto completo: 1 Base de dados: MEDLINE Idioma: En Ano de publicação: 2017 Tipo de documento: Article